Cargando…
Overexpression and Small Molecule-Triggered Downregulation of CIP2A in Lung Cancer
BACKGROUND: Lung cancer is the leading cause of cancer deaths worldwide, with a five-year overall survival rate of only 15%. Cancerous inhibitor of PP2A (CIP2A) is a human oncoprotein inhibiting PP2A in many human malignancies. However, whether CIP2A can be a new drug target for lung cancer is large...
Autores principales: | Ma, Liang, Wen, Zhe-Sheng, Liu, Zi, Hu, Zheng, Ma, Jun, Chen, Xiao-Qin, Liu, Yong-Qiang, Pu, Jian-Xin, Xiao, Wei-Lie, Sun, Han-Dong, Zhou, Guang-Biao |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3105001/ https://www.ncbi.nlm.nih.gov/pubmed/21655278 http://dx.doi.org/10.1371/journal.pone.0020159 |
Ejemplares similares
-
Overexpression of CIP2A is associated with poor prognosis in multiple myeloma
por: Liu, Xuewen, et al.
Publicado: (2017) -
Overexpression of CIP2A is an independent prognostic indicator in nasopharyngeal carcinoma and its depletion suppresses cell proliferation and tumor growth
por: Liu, Na, et al.
Publicado: (2014) -
CIP2A overexpression in Taiwanese oral cancer patients
por: Velmurugan, Bharath Kumar, et al.
Publicado: (2019) -
Downregulation of tumstatin expression by overexpression of ornithine decarboxylase
por: WANG, WEI, et al.
Publicado: (2013) -
Skp1 in lung cancer: clinical significance and therapeutic efficacy of its small molecule inhibitors
por: Liu, Yong-Qiang, et al.
Publicado: (2015)